Critical relevance of genomic gains of PRL‑3/EGFR/c‑myc pathway genes in liver metastasis of colorectal cancer

  • Authors:
    • Toshimichi Tanaka
    • Takeshi Kaida
    • Keigo Yokoi
    • Satoru Ishii
    • Nobuyuki Nishizawa
    • Hiroshi Kawamata
    • Hiroshi Katoh
    • Takeo Sato
    • Takatoshi Nakamura
    • Masahiko Watanabe
    • Keishi Yamashita
  • View Affiliations

  • Published online on: November 19, 2018     https://doi.org/10.3892/ol.2018.9728
  • Pages: 1257-1266
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The PRL‑3 gene is involved in the liver metastasis of colorectal cancer (CRC) and oncogene addiction to anticancer therapy. In the present study genomic gains in PRL‑3 and its pathway genes, c‑myc and EGFR, were investigated in order to determine their clinical relevance during metastatic formation in primary CRC and corresponding liver metastases. The genomic gain statuses of PRL‑3, EGFR, and c‑myc were investigated using quantitative polymerase chain reaction (qPCR) analysis in 35 samples of CRC and corresponding liver metastases. In the primary CRC specimens, genomic gains in PRL‑3, c‑myc, and EGFR were observed in 4, 4, and 13 cases, respectively. A genomic gain in one gene was observed in 18 cases, and these genomic gains were mutually exclusive. In the liver metastasis specimens, genomic gains were observed in 14, 8, and 13 cases, respectively. The copy numbers of PRL‑3 and c‑myc were significantly higher in the liver metastases than in the primary CRC specimens (P=0.03, P=0.009, respectively). A genomic gain in PRL‑3 was the most frequent gain in the liver metastases (P=0.004) and was partially redundant with a c‑myc genomic gain. EGFR genomic gains were consistent between the primary CRC and the liver metastases (P=0.0000008). In addition, a genomic gain in any of the 3 genes was observed in 23 cases (66%). Among the clinicopathological factors that were assessed, an EGFR genomic gain was significantly associated with tumour size in the primary CRC and the liver metastases (P=0.04). A c‑myc genomic gain was also significantly associated with the v factor of the primary tumours in the liver metastases (P<0.01). In conclusion, the genomic copy numbers of PRL‑3, c‑myc and EGFR were frequently characterised by aberrations in genomic gain in liver metastases from CRC; thus, these gene statuses exhibit potential for the identification of patients who are likely to respond positively to anticancer therapies.
View Figures
View References

Related Articles

Journal Cover

January-2019
Volume 17 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Tanaka T, Kaida T, Yokoi K, Ishii S, Nishizawa N, Kawamata H, Katoh H, Sato T, Nakamura T, Watanabe M, Watanabe M, et al: Critical relevance of genomic gains of PRL‑3/EGFR/c‑myc pathway genes in liver metastasis of colorectal cancer. Oncol Lett 17: 1257-1266, 2019
APA
Tanaka, T., Kaida, T., Yokoi, K., Ishii, S., Nishizawa, N., Kawamata, H. ... Yamashita, K. (2019). Critical relevance of genomic gains of PRL‑3/EGFR/c‑myc pathway genes in liver metastasis of colorectal cancer. Oncology Letters, 17, 1257-1266. https://doi.org/10.3892/ol.2018.9728
MLA
Tanaka, T., Kaida, T., Yokoi, K., Ishii, S., Nishizawa, N., Kawamata, H., Katoh, H., Sato, T., Nakamura, T., Watanabe, M., Yamashita, K."Critical relevance of genomic gains of PRL‑3/EGFR/c‑myc pathway genes in liver metastasis of colorectal cancer". Oncology Letters 17.1 (2019): 1257-1266.
Chicago
Tanaka, T., Kaida, T., Yokoi, K., Ishii, S., Nishizawa, N., Kawamata, H., Katoh, H., Sato, T., Nakamura, T., Watanabe, M., Yamashita, K."Critical relevance of genomic gains of PRL‑3/EGFR/c‑myc pathway genes in liver metastasis of colorectal cancer". Oncology Letters 17, no. 1 (2019): 1257-1266. https://doi.org/10.3892/ol.2018.9728